CARB-X launches 2026 funding round to address global burden of AMR
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) announced a funding solicitation targeting the global burden of antimicrobial resistance (AMR).
The CARB-X 2026 funding round includes four distinct product themes: direct-acting therapeutics for infections caused by Gram-negative bacteria, CARB-X Novel Chemistry for AMR Challenge – target-based therapeutics, non-vaccine approaches to prevent neonatal sepsis, and diagnostics for neonatal sepsis.
Target product profiles, minimal entry criteria, and Frequently Asked Questions for each theme are available on CARB-X.org. Expressions of interest may be submitted from 8 April 2026 at 10:00 ET – 22 April 2026 at 23:59 ET. Two public webinars will be held on 9 and 10 April to discuss the scope of the funding round, application process, and to answer questions. Register for the CARB-X newsletter to receive updates.
Applicants from around the globe are encouraged to apply, including from areas where the burden of antibiotic resistance is high. Academic centers and non-commercial developers are also encouraged, if they can demonstrate similar capabilities expected of a drug development industry partner. Applications will be reviewed by external experts, and final funding decisions are made by CARB-X.